In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...
In their 15th edition, the multifaceted digital media company ... and weight loss researchers. This years list was evaulated differently with diets being rated versus ranked. "Best Diets' updated ...
The company’s latest move expands its GLP-1 offering with prescribing capabilities, positioning Dario to capture a larger share of this lucrative space as demand for medical weight-loss ...